A retrospective observational study on the effectiveness and safety of vedolizumab with or without budesonide induction therapy among patients with moderate-to-severe Crohn's disease

被引：0
|
作者：
Weisshof, R. [1 ]
Vavricka, S. [2 ,3 ]
Pouillon, L. [4 ]
Braegger, F. [5 ]
Roset, M. [6 ]
Bent-Ennakhil, N. [5 ]
Ferrante, M. [7 ]
机构：
[1] Rambam Healthcare Campus, Dept Gastroenterol, Haifa, Israel
[2] Univ Hosp Zurich, Dept Gastroenterol & Hepatol, Zurich, Switzerland
[3] Ctr Gastroenterol & Hepatol AG, Zurich, Switzerland
[4] Imeldaziekenhuis Bonheiden, Imelda GI Clin Res Ctr, Bonheiden, Belgium
[5] Takeda Pharmaceut Int AG, Glattpark Opfikon, Switzerland
[6] Real World Solut, IQVIA, Barcelona, Spain
[7] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
来源：
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷
关键词：
D O I：
10.1093/ecco-jcc/jjab076.410
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P285
引用
收藏
页码：S317 / S318
页数：3
相关论文
共 50 条
  • [31] Comparative Efficacy and Safety of Adalimumab vs Vedolizumab in Managing Moderate-to-Severe Crohn's Disease: A Systematic Review and Meta-Analysis
    Merza, Nooraldin
    Al-Hillan, Alsadiq
    Mansur, Sarmed
    Merza, Fatima A.
    Nawras, Mohamad
    Dahiya, Dushyant Singh
    Boujemaa, Safa
    Naguib, Tarek
    Kobeissy, Abdallah A.
    Hassan, Mona
    Islam, Asm
    Alastal, Yaseen
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S705 - S706
  • [32] Effectiveness and safety of ustekinumab in bio-naive Crohn's disease patients: a multicentre observational retrospective study
    Delgado Teresa, Valdes
    Martin Raul, Olmedo
    Marisa, Iborra
    de Guise Claudia, Herrera
    Esteban, Fuentes-Valenzuela
    Luigi, Melcarne
    Ma Mar, Martin-Rodriguez
    Casso Lilyan, Kolle
    Parga Luisa, De Castro
    Diaz Angel, Ponferrada
    Lidon Raquel, Vicente
    Marcos Noemi, Mancenido
    Jimenez Benito, Velayos
    Saez Marta, Lazaro
    Cauce Beatriz, Lopez
    Gismero Francisco, Mesonero
    Pau, Gilabert Alvarez
    Federico, Arguelles-Arias
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [33] Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn's disease: a Belgian multicentric cohort study
    Alsoud, D.
    Franchimont, D.
    D'Heygere, F.
    Bossuyt, P.
    Vijverman, A.
    Van Hootegem, P.
    Sabino, J.
    Cremer, A.
    Vermeire, S.
    Ferrante, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I516 - I517
  • [34] Combination of vedolizumab and exclusive enteral nutrition in patients with moderate to severe Crohn's Disease
    Kang, J.
    Wang, J.
    Lu, Y.
    Li, J.
    Su, J.
    Ying, A.
    Ren, H.
    Zhou, Q.
    Wang, Y.
    Ding, Y.
    An, P.
    [J]. JOURNAL OF CROHNS & COLITIS, 2023, 17 : 808 - 808
  • [35] Comparison of Effectiveness and Safety of Ustekinumab and Adalimumab As Induction or Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis
    Chenna, Venkata Sai Harshabhargav
    Nagi, Talwinder K.
    Suarez, Zoilo K.
    Hernandez, Oscar L.
    Nageye, Maymona E.
    Reyaz, Nafisa
    Reyaz, Ibrahim
    Ali, Neelum
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (04)
  • [36] Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease
    Tuskey, Anne
    Behm, Brian W.
    [J]. CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2014, 7 : 173 - 179
  • [37] Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study
    Katsuyoshi Matsuoka
    Tadakazu Hisamatsu
    Yohei Mikami
    Takayuki Yamamoto
    Satoshi Motoya
    Shinichiro Shinzaki
    Ryuichi Iwakiri
    Kenkichi Sugiura
    Kunihiko Nishimura
    Mika Kajita
    Jovelle L. Fernandez
    [J]. Advances in Therapy, 2023, 40 : 2902 - 2914
  • [38] Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study
    Matsuoka, Katsuyoshi
    Hisamatsu, Tadakazu
    Mikami, Yohei
    Yamamoto, Takayuki
    Motoya, Satoshi
    Shinzaki, Shinichiro
    Iwakiri, Ryuichi
    Sugiura, Kenkichi
    Nishimura, Kunihiko
    Kajita, Mika
    Fernandez, Jovelle L.
    [J]. ADVANCES IN THERAPY, 2023, 40 (06) : 2902 - 2914
  • [39] Risankizumab Induction Therapy in Patients With Moderate-to-Severe Crohn's Disease with Intolerance or Inadequate Response to Conventional and/or Biologic Therapy: Results from the Phase 3 ADVANCE Study
    D'Haens, Geert R.
    Colombel, Jean Frederic
    Bossuyt, Peter
    Danese, Silvio
    Lim, Allen
    Lindsay, James
    Hisamatsu, Tadakazu
    Ran, Zhihua
    Rubin, David T.
    Neimark, Ezequiel
    Huang, Bidan
    Liao, Xiaomei
    Berg, Sofie
    Duan, W. Rachel
    Wallace, Kori
    Sandborn, William J.
    [J]. GASTROENTEROLOGY, 2021, 161 (02) : E28 - E28
  • [40] Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn's disease: A Canadian multi-center study
    Bessissow, Talat
    Narula, Neeraj
    Ma, Christopher
    In, Tracy S. H.
    Eberg, Maria
    Karra, Kinda
    Jairath, Vipul
    [J]. DIGESTIVE AND LIVER DISEASE, 2024, 56 (01) : 61 - 69
12345